Cargando…
Percutaneous Isolated Hepatic Perfusion for the Treatment of Unresectable Liver Malignancies
Liver malignancies are a major burden of disease worldwide. The long-term prognosis for patients with unresectable tumors remains poor, despite advances in systemic chemotherapy, targeted agents, and minimally invasive therapies such as ablation, chemoembolization, and radioembolization. Thus, the d...
Autores principales: | Burgmans, Mark C., de Leede, Eleonora M., Martini, Christian H., Kapiteijn, Ellen, Vahrmeijer, Alexander L., van Erkel, Arian R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4858556/ https://www.ncbi.nlm.nih.gov/pubmed/26718962 http://dx.doi.org/10.1007/s00270-015-1276-z |
Ejemplares similares
-
Prospective evaluation of percutaneous hepatic perfusion with melphalan as a treatment for unresectable liver metastases from colorectal cancer
por: Meijer, T. Susanna, et al.
Publicado: (2022) -
Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study
por: Meijer, T. Susanna, et al.
Publicado: (2020) -
Prospective Clinical and Pharmacological Evaluation of the Delcath System’s Second-Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan
por: de Leede, Eleonora M., et al.
Publicado: (2017) -
Erratum to: Prospective Clinical and Pharmacological Evaluation of the Delcath System’s Second-Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan
por: de Leede, Eleonora M., et al.
Publicado: (2017) -
Safety of Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Liver Metastases from Ocular Melanoma Using the Delcath Systems’ Second-Generation Hemofiltration System: A Prospective Non-randomized Phase II Trial
por: Meijer, T. Susanna, et al.
Publicado: (2019)